News

JPMorgan raised the firm’s price target on Insmed (INSM) to $135 from $111 and keeps an Overweight rating on the shares. The firm sees Brinsupri ...
William Blair initiated coverage of Insmed (INSM) with an Outperform rating. The firm believes that clinical and commercial execution with ...